Research Article
CAPTEM in Metastatic Well-Differentiated Intermediate to High Grade Neuroendocrine Tumors: A Single Centre Experience
Table 1
Baseline characteristics.
| | Baseline characteristics | Number (%) | | n=32 |
| | Median age (years) | | 58 | | Range | | 31-76 |
| | Gender | Male | 13 (40.6) | | Female | 19 (59.4) |
| | ECOG performance status | 1 | 30 (93.8) | | 2 | 2 (6.2) |
| | Primary site | Gastroenteropancreatic | 17 (53.1) | | (i) Pancreatic | 14 (43.8) | | (ii) Non Pancreatic | 3 (9.3) | | Lung | 12 (37.5) | | Unknown | 3 (9.4) |
| | ENETS Tumor Grade | 2 (Ki 67 – 2-20) | 21 (65.6) | | 3 (Ki 67> 20) | 11 (34.4) | | Ki67 >20- <55 | 7 (21.9) | | Ki67 > 55 | 4 (12.5) |
| | Sites of metastasis | Liver | 23 (72) | | Bones | 20 (62) | | Lymph nodes | 20 (62) | | Lung | 13 (41) | | Soft tissue deposits | 9 (28) | | Brain | 4 (12) | | Breast | 2 (6) | | Spleen | 1 (3) | | Peritoneal | 1 (3) | | Adrenal | 1 (3) |
| | Prior Treatment | No Treatment | 7 (21.9) | | Number of prior regimens | | | One line of prior therapy | 13 (40.6) | | 2 or more lines of prior therapy | 12 (37.5) | | SSA | 16 (50) | | Streptozocin/5-FU | 3 (9.4) | | Carboplatin and etoposide | 10 (31.3) | | FOLFIRI | 1 (3) | | Sunitinib | 1 (3) | | Everolimus | 5 (15.6) | | PRRT | 7 (21.9) |
|
|
Abbreviations
ECOG - Eastern Cooperative Oncology Group
ENETS - European Neuroendocrine Tumor Society
SSA - somatostatin analog
5-FU – 5 – Fluorouracil
PRRT - Peptide receptor radionuclide therapy
|
